A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR

Inclusion Criteria: * Subjects with Type II diabetic nephropathy, who have been treated with angiotensin converting enzyme-inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) * Glycosylated haemoglobin (HbA1c) ≤10.5% * An estimated glomerular filtration rate (eGFR) ≥30-\<60 mL/min/1.73m\^2 * Subject with albuminuria Exclusion Criteria: * History of Type I diabetes, pancreas or β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy * Serum potassium level \<3.5 or \>5.0 mmol/L * Subjects who had acute kidney injury (AKI) within 3 months prior to baseline or have undergone renal dialysis at any time prior to randomisation * Subjects with a history of renal transplant * Subjects with clinically significant hypotension